AI Engines For more Details: Perplexity Kagi Labs You
Cough: Carbetapentane citrate is indicated for the temporary relief of cough due to minor throat and bronchial irritation associated with the common cold, bronchitis, sinusitis, or other respiratory tract infections. It helps to suppress dry, non-productive coughs by decreasing the frequency and intensity of coughing episodes.
Symptomatic Relief: By suppressing coughing, carbetapentane citrate can provide symptomatic relief from cough-related discomfort, including irritation of the throat and chest, as well as difficulty sleeping due to frequent coughing episodes.
Non-Narcotic Cough Suppressant: Carbetapentane citrate is classified as a non-narcotic antitussive, meaning it does not contain opioids or narcotics like codeine or dextromethorphan, which are commonly found in other cough suppressant medications. This makes it a preferred option for individuals who may be sensitive to or wish to avoid opioids.
Dosing and Administration: Carbetapentane citrate is typically administered orally as a liquid suspension or syrup. It is important to follow the dosage instructions provided by a healthcare professional or as indicated on the medication label. Overuse or misuse of cough suppressants can lead to adverse effects or mask underlying medical conditions.
Safety Considerations: While generally considered safe when used as directed, carbetapentane citrate may cause side effects in some individuals, including drowsiness, dizziness, headache, nausea, vomiting, constipation, and dry mouth. It may also interact with other medications, such as sedatives or alcohol, leading to increased drowsiness or impairment.
Pediatric Use: Carbetapentane citrate may be used in children as directed by a healthcare provider. However, it is important to use caution and follow age-appropriate dosing guidelines, as misuse or overdose can be harmful, especially in young children.
Pregnancy and Breastfeeding: The safety of carbetapentane citrate during pregnancy and breastfeeding has not been well established. Pregnant or breastfeeding individuals should consult with a healthcare professional before using this medication to weigh the potential risks and benefits.
Underlying Conditions: Carbetapentane citrate may not be suitable for individuals with certain underlying medical conditions, such as asthma, chronic obstructive pulmonary disease (COPD), or respiratory depression. It is important to inform a healthcare provider about any pre-existing health conditions before using this medication.
Duration of Use: Carbetapentane citrate is intended for short-term use to provide temporary relief from coughing associated with acute respiratory infections. Prolonged or excessive use may lead to tolerance, dependence, or rebound cough. If cough symptoms persist or worsen despite treatment, medical evaluation is recommended.
Storage and Disposal: Carbetapentane citrate should be stored at room temperature away from moisture and heat. Unused or expired medication should be properly disposed of according to local regulations or guidelines to prevent accidental ingestion or misuse.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 2.7 | 0.3 | 8 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.3 | 1.6 | 1.06 |
| Allergies | 3.3 | 1.9 | 0.74 |
| Allergy to milk products | 1.4 | 1.6 | -0.14 |
| Alopecia (Hair Loss) | 0.9 | 0.9 | |
| Alzheimer's disease | 5 | 4.5 | 0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.5 | 0.6 | 3.17 |
| Ankylosing spondylitis | 3.5 | 1.5 | 1.33 |
| Anorexia Nervosa | 1.2 | 2.4 | -1 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.3 | 1.33 |
| Asthma | 4.5 | 2.4 | 0.88 |
| Atherosclerosis | 1.7 | 1.1 | 0.55 |
| Atrial fibrillation | 2.9 | 2.4 | 0.21 |
| Autism | 6.7 | 6.5 | 0.03 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.5 | 2.5 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 1 | 1 | |
| Cancer (General) | 0.9 | 0.7 | 0.29 |
| Carcinoma | 4.6 | 2.2 | 1.09 |
| Celiac Disease | 1.7 | 2.9 | -0.71 |
| Cerebral Palsy | 1.5 | 0.8 | 0.88 |
| Chronic Fatigue Syndrome | 2.9 | 3 | -0.03 |
| Chronic Kidney Disease | 3.6 | 2.2 | 0.64 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.1 | 1.7 | 0.24 |
| Chronic Urticaria (Hives) | 1.7 | 0.6 | 1.83 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 0.8 | 1 |
| Cognitive Function | 2.2 | 1.6 | 0.38 |
| Colorectal Cancer | 6.7 | 2.5 | 1.68 |
| Constipation | 1.2 | 0.5 | 1.4 |
| Coronary artery disease | 2.4 | 2.1 | 0.14 |
| COVID-19 | 5.5 | 6.5 | -0.18 |
| Crohn's Disease | 7 | 4.5 | 0.56 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.9 | 1.4 | -0.56 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.9 | 1.1 | 0.73 |
| Denture Wearers Oral Shifts | 1.8 | 1.8 | |
| Depression | 7 | 6.3 | 0.11 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 1.8 | 0.28 |
| Endometriosis | 2.8 | 1.7 | 0.65 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.1 | 1.8 | 0.72 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.2 | 1 | 2.2 |
| Functional constipation / chronic idiopathic constipation | 3.2 | 2.3 | 0.39 |
| gallstone disease (gsd) | 3.2 | 1.3 | 1.46 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 0.6 | 1.5 |
| Generalized anxiety disorder | 2.8 | 1.2 | 1.33 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.7 | 0.4 | 0.75 |
| Graves' disease | 1.6 | 2.6 | -0.63 |
| Gulf War Syndrome | 0.5 | 1 | -1 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 2.9 | 1.5 | 0.93 |
| Heart Failure | 3.5 | 1.4 | 1.5 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.5 | 0.3 | 4 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.3 | 1.67 |
| hyperglycemia | 2.4 | 1.5 | 0.6 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 4 | 2.7 | 0.48 |
| Hypothyroidism | 0.1 | 0.6 | -5 |
| Hypoxia | 3.3 | 0.3 | 10 |
| IgA nephropathy (IgAN) | 1.6 | 2.6 | -0.63 |
| Inflammatory Bowel Disease | 6.9 | 5.2 | 0.33 |
| Insomnia | 2 | 2.4 | -0.2 |
| Intelligence | 0.9 | 0.1 | 8 |
| Intracranial aneurysms | 1 | 0.3 | 2.33 |
| Irritable Bowel Syndrome | 6 | 3.5 | 0.71 |
| ischemic stroke | 1.9 | 1.7 | 0.12 |
| Liver Cirrhosis | 6.5 | 4.4 | 0.48 |
| Long COVID | 5.4 | 4.5 | 0.2 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.9 | 0.9 | 0 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.6 | 0.3 | 4.33 |
| ME/CFS with IBS | 0.5 | 0.8 | -0.6 |
| ME/CFS without IBS | 1.4 | 1.3 | 0.08 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.5 | 0.7 | -0.4 |
| Metabolic Syndrome | 6.3 | 4.8 | 0.31 |
| Mood Disorders | 7 | 5.4 | 0.3 |
| multiple chemical sensitivity [MCS] | 1.3 | 1.3 | |
| Multiple Sclerosis | 5.2 | 3.5 | 0.49 |
| Multiple system atrophy (MSA) | 0.8 | 0.3 | 1.67 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 1.8 | -5 |
| Neuropathy (all types) | 0.7 | 1.7 | -1.43 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.7 | 2.8 | 0.68 |
| NonCeliac Gluten Sensitivity | 1.5 | 0.6 | 1.5 |
| Obesity | 7.4 | 7.4 | 0 |
| obsessive-compulsive disorder | 2.8 | 3.3 | -0.18 |
| Osteoarthritis | 2.7 | 1 | 1.7 |
| Osteoporosis | 2.2 | 1.5 | 0.47 |
| pancreatic cancer | 1.3 | 0.3 | 3.33 |
| Parkinson's Disease | 6.3 | 5.5 | 0.15 |
| Polycystic ovary syndrome | 4.1 | 2.3 | 0.78 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 1.2 | 1.2 | 0 |
| Primary sclerosing cholangitis | 2.4 | 1.2 | 1 |
| Psoriasis | 2 | 2.1 | -0.05 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6 | 3.7 | 0.62 |
| Rosacea | 0.5 | 0.7 | -0.4 |
| Schizophrenia | 4.8 | 2.5 | 0.92 |
| scoliosis | 0.3 | 0.4 | -0.33 |
| Sjögren syndrome | 2.3 | 2.2 | 0.05 |
| Sleep Apnea | 1.4 | 1.1 | 0.27 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 1.7 | |
| Stress / posttraumatic stress disorder | 3.1 | 2.1 | 0.48 |
| Systemic Lupus Erythematosus | 4 | 1.6 | 1.5 |
| Tic Disorder | 0.6 | 1.3 | -1.17 |
| Tourette syndrome | 1 | 0.3 | 2.33 |
| Type 1 Diabetes | 2.5 | 2.2 | 0.14 |
| Type 2 Diabetes | 6.5 | 4.6 | 0.41 |
| Ulcerative colitis | 5.5 | 3.3 | 0.67 |
| Unhealthy Ageing | 4.1 | 2.1 | 0.95 |
| Vitiligo | 1.8 | 1.1 | 0.64 |
